AI Tool to Be Tested in NHS Hospitals for Prostate Cancer Diagnosis
A new artificial intelligence tool designed to aid in the diagnosis and treatment planning for prostate cancer will be tested across several National Health Service hospitals, researchers announced today.
The £1.9 million Vanguard Path study, funded by Prostate Cancer UK and led by researchers at the University of Oxford, is slated to run for three years and will evaluate the ArteraAI Prostate Biopsy Assay using biopsy samples from over 4,000 men. The tool analyzes digitized biopsy images to generate a personalized risk score, potentially improving treatment decisions. Early trials have indicated its effectiveness in identifying patients who would benefit most from the drug abiraterone, and further research suggests it could also refine treatment plans for less aggressive cancers.
The study will initially analyze existing biopsy samples with known outcomes to validate the tool’s predictive capabilities within a UK patient population. Testing will then take place at North Bristol NHS Trust, Oxford University Hospitals NHS Foundation Trust, and NHS Greater Glasgow and Clyde, where clinicians will compare their treatment recommendations with those suggested by the AI. “If and when this gets implemented, you could use one tool irrespective of where you are on the aggressiveness scale, to make a very clinically and life-enhancingly important decision for each of those men,” said Dr. Matthew Hobbs, director of research at Prostate Cancer UK. Accurate diagnosis and treatment are crucial, as prostate cancer is the most common cancer in men in the UK.
Experts hope the tool will help reduce both under-treatment and over-treatment of prostate cancer, ensuring patients receive the most appropriate care. Public Health Minister Ashley Dalton welcomed the trial, stating, “This groundbreaking research could be a huge step forward, demonstrating the power of technology to potentially transform lives and improve cancer outcomes.” The trial will assess the tool’s scientific validity, cost-effectiveness, and impact on treatment decisions before potential widespread implementation within the NHS.
